Vivos Announces New Review Study By Dr. Dave Singh to be

Published in Journal of Sleep Disorders

Review Focuses on Remodeling of the Airway to Treat Obstructive Sleep Apnea


DENVER (February 23, 2018) – Vivos Therapeutics, a world leader in the treatment of obstructive sleep apnea, announced today that an important review paper authored by Dr. Dave Singh, DMD, PhD, DDSc, will appear in the March issue of the Journal of Sleep Disorders: Treatment and Care. The paper is entitled “Physiologic Remodeling of the Upper Airway: Pneumopedics.”

A longtime and renowned professor and researcher in the areas of craniofacial epigenetics, sleep disordered breathing and orthodontics, Dr. Singh’s review supports his novel concept of non-surgical upper airway remodeling and pneumopedics; and follows his February 2018 case report in the Journal of Craniomandibular and Sleep Practice, which illustrates the mechanism of biomimetic oral appliance therapy.

“We know that a very significant percentage of OSA and SDB cases are undiagnosed, and we also know that current treatments primarily address the symptoms of these difficult conditions,” noted Dr. Singh. “My research continues to drive understanding throughout the medical and dental communities about new ways to treat, and potentially resolve, mild to moderate sleep apnea.

Dr. Singh serves on the clinical advisory board for Vivos as well as the Board of the American Sleep and Breathing Academy.


Media Contact: Shannon Michael, SnappConner PR,


About Vivos

Founded in 2016, Vivos Therapeutics combines breakthrough technology for specially designed oral appliances with proprietary clinical protocols for obstructive sleep apnea (OSA) treatment that can restore and enhance the human airway. Because its patented FDA Class I and II medical devices are thought to be the first treatment that addresses the root causes of OSA, Vivos can improve the airway so that further clinical intervention may no longer be required in some cases. Other treatments for this insidious and dangerous condition require lifetime treatment, which has a significant impact on U.S. healthcare costs. Because the Vivos System is all-natural, non-invasive and non-pharmaceutical, many more patients will be able to receive treatment from the 750+ (and growing) independent providers who have been trained and certified in the Vivos methodology and who have already treated more than 8,000 patients. The company also is creating Vivos Breathing Wellness Centers in major metro areas, working with licensed and trained local medical and dental professionals. For more information, visit